[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100109306":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":28,"centralContacts":17,"locations":33,"responsibleParty":45,"collaborators":17,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":17,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":17,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":72,"whyStopped":17,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"1","EXPERIMENTAL","AZD4818",[13],"Drug: AZD4818",{"label":15,"type":16,"description":17,"interventionNames":18},"2","PLACEBO_COMPARATOR",null,[19],"Drug: Placebo",[21,25],{"type":22,"name":11,"description":23,"armGroupLabels":24,"otherNames":17},"DRUG","Dry powder, inhalation, b.i.d, 10 + 1\u002F2 days or 20 + 1\u002F2 days",[9],{"type":22,"name":26,"description":17,"armGroupLabels":27,"otherNames":17},"Placebo",[15],[29],{"name":30,"affiliation":31,"role":32},"Michio Yagi","Osaka Pharmacology Clinical Research Hospital","PRINCIPAL_INVESTIGATOR",[34],{"facility":35,"status":17,"city":36,"state":36,"zip":17,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":17},"Research Site","Osaka","Japan","JP",{"type":40,"coordinates":41},"Point",[42,43],135.50107,34.69379,{"lat":43,"lon":42},{"type":17,"investigatorFullName":17,"investigatorTitle":17,"investigatorAffiliation":17,"oldNameTitle":46,"oldOrganization":47},"Bengt Larsson\u002FMD PhD, Medical Science Director, RITA EPT2","AstraZeneca Pharmaceuticals","100109306","phase-1-safety-tolerability-and-pharmacokinetics-of-inhaled-doses-of-azd4818-in-healthy-japanese-male-volunteers-100109306",false,"NCT00687232","Safety, Tolerability and Pharmacokinetics of Inhaled Doses of AZD4818 in Healthy Japanese Male Volunteers","A Randomised, Placebo-controlled Single-blind, Single-centre Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Inhaled Doses of AZD4818 in Healthy Japanese Male Volunteers","Inclusion Criteria:\n\n* Provision of informed consent\n* Body Mass Index (BMI) between 18.0-27.0 kg\u002Fm2\n* No clinically relevant abnormal findings\n\nExclusion Criteria:\n\n* Acute illness which requires medical intervention\n* Definite or suspected personal history of adverse drug reactions or drug hypersensitivity.\n* Clinical relevant disease or disorder (past or present)\n* A history of respiratory disorders",true,"MALE","20 Years","45 Years",{"count":60,"type":61},30,"ESTIMATED","INTERVENTIONAL",[64],"PHASE1","The purpose is to investigate safety and tolerability of single and multiple ascending inhaled doses of AZD4818 in healthy Japanese male volunteers.",[67],"Healthy",[69,37,70,71],"Phase I","Japanese","inhalation","COMPLETED","2010-11-30",{"date":75,"type":61},"2010-12-01",{"date":77,"type":17},"2008-01",{"date":79,"type":80},"2008-05","ACTUAL",{"name":5,"class":6},1]